DVADaVita
Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similar terms refer to DaVita Inc. and its consolidated subsidiaries. 10-K, Item 1
- Headquarters
- Denver, CO
- CEO
- Javier Rodriguez
- Next results
- around Feb 1, 2027
All key numbers (37) From EDGAR
| EPS (ttm) | 13.49 | Sales (ttm) | 14.2B | Net income (ttm) | 920.1M | Sales growth | +6.5% | EPS growth | -8.3% | Sales Q/Q | +4.6% |
| Free cash flow | 1.3B | Gross margin | - | Oper. margin | 15.0% | Net margin | 6.5% | FCF margin | 9.1% | ROE | n/m |
| ROA | 5.2% | R&D / sales | - | Dividend | - | Debt/Eq | n/m | Curr. ratio | 1.41 | Cash | 495.6M |
| Op. cash flow (ttm) | 1.9B | EBITDA | 2.8B | EBITDA margin | 20.2% | Net debt | 10.3B | Quick ratio | 1.36 | Interest cover | 3.79 |
| Tax rate | 21.8% | Stock pay / sales | 1.0% | Shares out. | 62.9M | Shares Y/Y | -13.0% | Book / share | -9.40 | Cash / share | 7.88 |
| Sales / share | 225.24 | Asset turnover | 0.80 | Days sales out. | 65 | Sales 3Y CAGR | +5.5% | Sales 5Y CAGR | +3.4% | EPS 3Y CAGR | +18.9% |
| EPS 5Y CAGR | +9.3% |
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
DVA against Health care peers
Ten years, side by side → · All 60 →Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How
Every dot is one of the 60 companies, the better end on the right. Hover a dot for the company.
| Company | Revenue (ttm) | Sales growth | Gross margin | Net margin | ROE | FCF margin | Debt / equity |
|---|---|---|---|---|---|---|---|
| DVA DaVita | $14.2B | +6.5% | - | 6.5% | - | 9.1% | - |
| VTRS Viatris | $14.7B | -3.0% | 35.3% | -4.1% | -4.4% | 14.3% | 0.97 |
| LH Labcorp | $14.6B | +7.2% | 29.0% | 6.9% | 11.3% | 8.8% | 0.66 |
| HSIC Henry Schein | $13.7B | +4.0% | 31.6% | 3.1% | 13.3% | 4.1% | 1.12 |
| VRTX Vertex Pharmaceuticals | $13.0B | +8.9% | 85.5% | 30.7% | 19.0% | 24.7% | 0.22 |
| DGX Quest Diagnostics | $11.8B | +11.8% | 33.1% | 9.5% | 14.8% | 11.6% | 0.73 |
Profitability
1 of 2- !Net margin below the peer median6.5% vs 9.6%
- ✓A profit in every one of 10 years
Balance sheet
1 of 4- !Interest covered less than 5 timesOperating income is 3.8× interest expense
- !Equity below zeroDebt $10.8B, equity −$591.1M
- ✓Current assets cover current liabilitiesCurrent ratio 1.41
- !Net debt over 3 years of free cash flow$10.2B net debt, 7.9 years
Cash and shareholders
3 of 3- ✓Free cash flow positive in every one of 10 years$1.3B last year
- ✓Share count down over 5 years−38.1%
- ✓Cash from operations above net income$1.9B vs $746.8M
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
What the debt is made of, and when it is due
balance sheet of Sep 30, 2026The debt note's own lines, 2025-12-31
| Line, as the company names it | Kind | Rate | Fixed or floating | Amount |
|---|---|---|---|---|
| Senior Notes 4.625% due 2030 | Notes and bonds | – | not stated | $2.8B |
| Senior Notes 3.75% due 2031 | Notes and bonds | – | not stated | $1.5B |
| Senior Notes 6.875% due 2032 | Notes and bonds | – | not stated | $1.0B |
| Senior Notes 6.75% due 2033 | Notes and bonds | – | not stated | $1.0B |
From the debt note in the 10-K's XBRL (0000927066-26-000012), as the company tags it: by issue, by year, by currency or by kind. Lines from two ways of cutting the same debt can overlap, so they are not added up. Fixed or floating is read from the line's own name only; "not stated" when it says neither.
Left: the debt lines on the balance sheet (XBRL). Right: the principal due each year, from the debt note's maturity schedule; it can differ a little from the balance sheet, which shows the debt net of discounts and fees. Leases are not counted. The full schedule →
Revenue and net income, FY2016 to FY2025
Revenue 13.6B Net income 746.8MFrom XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →
DVA's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
The segments changed
10-K filed 2026-02-11Compared with the 10-K of Feb 13, 2025: new segments U S Dialysis And Related Lab Services, Other - Ancillary services .
When a company changes its segments, the years before are usually recast, so growth by segment is not comparable with what earlier 10-Ks showed. Found by comparing the segments with revenue in the last two 10-Ks (XBRL) and by the 10-K's own words, without AI.
Revenue by business segment
year to Dec 31, 2025| Revenue | Share | vs year before | |
|---|---|---|---|
| US Dialysis And Related Lab Services With Intersegment | 11.8B | 86.3% | +3.5% |
| U S Dialysis And Related Lab Services | 11.7B | 86.0% | +3.6% |
| Other - Ancillary services | 1.9B | 14.0% | +27.7% |
| Other Operating Segments With Intersegment | 1.3B | 9.5% | +34.6% |
10-K 0000927066-26-000012, segment and revenue notes (XBRL).
Income statement
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.7B | 10.9B | 11.4B | 11.4B | 11.6B | 11.6B | 11.6B | 12.1B | 12.8B | 13.6B |
| SG&A | 1.1B | 1.1B | 1.1B | 1.1B | 1.2B | 1.2B | 1.4B | 1.5B | 1.5B | 1.7B |
| Operating income | 2.0B | 1.8B | 1.5B | 1.6B | 1.7B | 1.8B | 1.3B | 1.6B | 2.1B | 2.0B |
| Interest expense | 394.0M | 406.3M | 461.9M | 419.6M | 282.9M | 267.0M | 339.2M | 374.0M | 435.2M | 539.9M |
| Pretax income | 1.6B | 1.4B | 1.0B | 1.2B | 1.3B | 1.5B | 966.3M | 1.2B | 1.5B | 1.3B |
| Income tax | 431.8M | 323.9M | 258.4M | 279.6M | 313.9M | 306.7M | 198.1M | 220.1M | 279.7M | 293.1M |
| Net income | 879.9M | 663.6M | 159.4M | 811.0M | 773.6M | 978.5M | 560.4M | 691.5M | 936.3M | 746.8M |
| EPS (diluted) | 4.29 | 3.47 | 0.92 | 5.27 | 6.31 | 8.90 | 5.85 | 7.42 | 10.73 | 9.84 |
| Diluted shares | 204.9M | 191.3M | 172.4M | 153.8M | 122.6M | 109.9M | 95.8M | 93.2M | 87.3M | 75.9M |
| Depreciation & amortization | 494.9M | 544.1M | 574.8M | 600.9M | 616.6M | 667.8M | 721.1M | 736.5M | 716.4M | 708.3M |
| EBITDA | 2.5B | 2.4B | 2.1B | 2.2B | 2.3B | 2.5B | 2.1B | 2.3B | 2.8B | 2.8B |
| Operating margin | 19.0% | 16.7% | 13.4% | 14.4% | 14.7% | 15.5% | 11.5% | 13.2% | 16.3% | 15.0% |
| Net margin | 8.2% | 6.1% | 1.4% | 7.1% | 6.7% | 8.4% | 4.8% | 5.7% | 7.3% | 5.5% |
| Revenue growth | - | +1.6% | +4.9% | -0.1% | +1.4% | +0.6% | -0.1% | +4.6% | +5.6% | +6.5% |
| EPS growth | - | -19.1% | -73.5% | +473% | +19.7% | +41.0% | -34.3% | +26.8% | +44.6% | -8.3% |
Balance sheet
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | 674.8M | 508.2M | 323.0M | 1.1B | 325.0M | 461.9M | 244.1M | 380.1M | 794.9M | 676.4M |
| Short-term investments | 307.0M | 32.8M | 2.9M | 11.6M | 20.1M | 22.3M | 77.7M | 11.6M | 51.1M | 24.3M |
| Receivables | 1.5B | 1.7B | 1.9B | 1.8B | 1.8B | 2.0B | 2.1B | 2.0B | 2.1B | 2.4B |
| Inventory | 160.4M | 181.8M | 107.4M | 97.9M | 111.6M | 107.4M | 109.1M | 143.1M | 134.6M | 160.6M |
| Current assets | 4.0B | 8.8B | 8.4B | 3.7B | 3.1B | 3.2B | 3.2B | 3.1B | 3.7B | 4.1B |
| Property & equipment | 2.9B | 3.1B | 3.4B | 3.5B | 3.5B | 3.5B | 3.3B | 3.1B | 2.9B | 2.8B |
| Goodwill | 6.0B | 6.6B | 6.8B | 6.8B | 6.9B | 7.0B | 7.1B | 7.1B | 7.4B | 7.5B |
| Total assets | 18.8B | 19.0B | 19.1B | 17.3B | 17.0B | 17.1B | 16.9B | 16.9B | 17.3B | 17.5B |
| Accounts payable | 456.6M | 509.1M | 463.3M | 403.8M | 434.3M | 402.0M | 479.8M | 514.5M | 547.2M | 696.1M |
| Current liabilities | 2.7B | 3.1B | 4.9B | 2.4B | 2.5B | 2.4B | 2.6B | 2.6B | 3.0B | 3.1B |
| Total debt | 9.1B | 9.3B | 10.1B | 8.1B | 8.1B | 8.9B | 8.9B | 8.4B | 9.4B | 10.3B |
| Total liabilities | 12.9B | 13.1B | 14.1B | 13.8B | 14.1B | 14.8B | 14.7B | 14.2B | 15.2B | 16.3B |
| Shareholders' equity | 4.6B | 4.7B | 3.7B | 2.1B | 1.4B | 755.5M | 712.3M | 1.1B | 121.1M | -651.1M |
| Retained earnings | 3.7B | 3.6B | 2.7B | 1.4B | 852.5M | 354.3M | 174.5M | 598.3M | 1.5B | -328.4M |
Cash flow
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.0B | 1.9B | 1.8B | 2.1B | 2.0B | 1.9B | 1.6B | 2.1B | 2.0B | 1.9B |
| Capital spending | 829.1M | 905.2M | 987.1M | 766.5M | 674.5M | 641.5M | 603.4M | 568.0M | 555.4M | 575.9M |
| Free cash flow | 1.1B | 1.0B | 784.5M | 1.3B | 1.3B | 1.3B | 961.1M | 1.5B | 1.5B | 1.3B |
| Stock-based pay (added back) | 38.3M | 35.1M | 73.1M | 67.8M | 91.5M | 102.2M | 95.4M | 112.4M | 102.8M | 140.0M |
| Dividends paid | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buybacks | 1.1B | 802.9M | 1.2B | 2.4B | 1.5B | 1.5B | 802.2M | 272.2M | 1.4B | 1.3B |
| Acquisitions | 563.9M | 803.9M | 183.2M | 100.9M | 182.0M | 187.1M | 57.3M | 26.4M | 246.1M | 117.5M |
| Debt raised | 52.0B | 51.0B | 59.9B | 38.5B | 4.0B | 1.6B | 2.4B | 2.5B | 6.6B | 5.6B |
| Investing cash flow | -1.2B | -1.4B | -1.0B | 3.0B | -825.4M | -784.7M | -630.3M | -771.8M | -771.4M | -654.9M |
| Financing cash flow | -1.4B | -766.3M | -625.4M | -4.7B | -1.8B | -1.1B | -1.1B | -1.2B | -816.9M | -1.4B |
Stock-based pay and leases
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based pay (expense) | 38.3M | 35.1M | 73.1M | 67.8M | 91.5M | 102.2M | 95.4M | 112.4M | 102.8M | 140.0M |
| Stock-based pay / revenue | 0.4% | 0.3% | 0.6% | 0.6% | 0.8% | 0.9% | 0.8% | 0.9% | 0.8% | 1.0% |
| Operating lease cost | - | - | - | - | - | 673.9M | 679.8M | 692.8M | 689.1M | 702.2M |
| Operating lease cash paid | - | - | - | 637.7M | 661.3M | 684.2M | 696.3M | 708.2M | 719.3M | 724.6M |
| Finance lease principal paid | - | - | - | 25.7M | 24.8M | 22.4M | 24.3M | 26.5M | 29.6M | 29.4M |
| Right-of-use assets | - | - | 0 | 2.8B | 2.9B | 2.8B | 2.7B | 2.5B | 2.4B | 2.4B |
| Operating lease liabilities | - | - | 0 | 3.1B | 3.1B | 3.1B | 2.9B | 2.7B | 2.6B | 2.6B |
| Finance lease liabilities | - | - | 282.7M | 268.5M | 274.3M | - | 273.7M | 255.5M | 216.4M | 185.1M |
From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.
Work on DVA in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/DVA/export.csv") into a cell.